Skip to main content

Matilde Lleonart Pajarin

Institutions of which they are part

Head of group
Biomedical Research in Cancer Stem Cells
Vall Hebron Institut de Recerca

Matilde Lleonart Pajarin

Institutions of which they are part

Head of group
Biomedical Research in Cancer Stem Cells
Vall Hebron Institut de Recerca

Research lines

Study of new genes involved in proliferation

Searching for new proliferative genes/tumor suppressor genes is being performed at our laboratory by carring out genetic screens. By the use of retroviral vectors as carriers of a cDNA libraries (formed by mRNA from murine embryonic stem cells), primary cells are infected and screening for those clones able to bypass senescence are selected for further characterization. The marked morphological heterogeneity observed in several tumorigenic process, support the hypothesis that several cancers have their origin in a stem cell. It is believed that genes expressed by embryonic stem cells, may play an important role in the tumorigenic mechanism.This project unravels the effect of immortal genes existing in embryonic stem cells, when are forced to be expressed in primary and thereby mortal cells. These immortal genes are future candidate markers in tumors with potential prognosis value. The novel genes discovered, are being analyzed in the biopsies from patients with different kinds of tumors collected at the Pathology Department of the Vall d´Hebrón Hospital.

IP: Matilde Lleonart Pajarin

Identificación y caracterización de genes/microRNAs en tumores humanos asociados a mal pronóstico

En base a arrays de microRNAs y mRNAs efectuados a partir de tumores humanos, identificamos los más desregulados entre tejidos normales y tumorales para caracterizarlos a nivel molecular.

IP: Matilde Lleonart Pajarin

Identificación y caracterización de poblaciones de CSCs ("cancer stem cells") en tumores

A partir de diversos tipos de cánceres que incluyen desde mama, pulmón, cabeza y cuello, en particular los más letales (faringe y laringe), aislamos poblaciones de CSCs para determinar su caracterización completa e implicación en la clínica.

IP: Matilde Lleonart Pajarin

Detección precoz de cáncer mamario antes de que éste se manifieste

A partir de datos preliminares de arrays, hemos caracterizado algunos microRNAs/mRNAs relevantes en tumores. Actualmente los estamos analizando a nivel de pacientes con cáncer en sangre como posible método predictivo antes de la aparición del tumor.

IP: Matilde Lleonart Pajarin

Projects

Degradadores moleculares de SFN para sensibilizar células tumorales de cabeza y cuello (HNSCC) resistentes a terapias convencionales (ANTCANRES)

IP: Matilde Lleonart Pajarin
Collaborators: Yoelsis Garcia Mayea
Funding agency: Fundació Institut Bioenginyeria de Catalunya
Funding: 0.01
Reference: K9086
Duration: 24/07/2023 - 24/07/2024

Beca VHIR PhD

IP: Matilde Lleonart Pajarin
Collaborators: Sira Rodrigo Bosch, Laia Perez Lasarte, Marina Bataller Fernández
Funding agency: Fundació Institut de Recerca HUVH
Funding: 69188.74
Reference: VPHD/MARINA_B
Duration: 01/04/2023 - 31/03/2026

New compounds targeting head and neck cancer as Trojan horses against chemoresistant cells

IP: Matilde Lleonart Pajarin
Collaborators: Yoelsis Garcia Mayea, Marina Bataller Fernández, Gabriela Isabel Fuentes Llopis, Almudena Sanchez Garcia
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 20000
Reference: 2023 LLAV 00102
Duration: 01/02/2024 - 31/07/2024

Therapeutical approaches against chemoresistant cancers

IP: Matilde Lleonart Pajarin
Collaborators: Yoelsis Garcia Mayea, Fco. Xavier De la Cruz Montserrat, Juan Lorente Guerrero, Natalia Padilla Sirera, Marina Bataller Fernández, Almudena Sanchez Garcia, Selen Ozkan
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 01205
Duration: 01/01/2022 - 30/06/2025

Related news

The Biomedical Research in Cancer Stem Cells group at VHIR has identified a new therapeutic target and is working to find new therapies for this type of tumor.

On World Cancer Research Day, we highlight the oncology research model of the Vall d'Hebron Campus that allows laboratory results to be transferred as quickly as possible to clinical practice.

Vall d’Hebron ha celebrat avui la Jornada del Dia Mundial contra el Càncer, una malaltia cada cop més freqüent que patiran al llarg de la vida un de cada dos homes i una de cada tres dones del nostre entorn.

Related professionals

Marc-Enric Fernandez Exposito

Marc-Enric Fernandez Exposito

Tècnic/a Grau Superior
Unitat legal
Direcció Jurídica
Read more
Bernat Massó Carreras

Bernat Massó Carreras

Research technician
Reconstructive Surgery of the Locomotor System
Read more
Xavier Serra Ruiz

Xavier Serra Ruiz

Research technician
Physiology and Pathophysiology of the Digestive Tract
Read more
Gemma  Duarri Llado

Gemma Duarri Llado

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.